<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01395797</url>
  </required_header>
  <id_info>
    <org_study_id>6255</org_study_id>
    <secondary_id>R01DA031022</secondary_id>
    <nct_id>NCT01395797</nct_id>
  </id_info>
  <brief_title>Pioglitazone for Heroin and for Nicotine Dependence</brief_title>
  <official_title>Effects of Pioglitazone, a PPARγ Agonist, on the Abuse Liability of Heroin and of Nicotine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Omeros Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the proposed research is to improve the effectiveness of treatments for opioid
      and for nicotine dependence by testing a novel pharmacological strategy. Specifically,
      pioglitazone, a peroxisome proliferator-activated gamma receptor (PPARγ) agonist, will be
      used as an adjunct to agonist-based treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although treatments for opioid and for nicotine dependence exist, these medications are not
      universally effective as many patients are unable to stop using or relapse rapidly,
      suggesting that treatment with a single agent alone is insufficient to facilitate cessation
      of use in many patients. Targeting additional pathways that may contribute to the maintenance
      of drug-taking behaviors or relapse may be a more effective strategy to treat individuals
      resistant to first-line approaches.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The funding period ended.
  </why_stopped>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Drug's Break Point</measure>
    <time_frame>Following 2 weeks of Pioglitazone (PIO) maintenance.</time_frame>
    <description>Number of operant responses (mouse clicks) participants were willing to provide in order to receive the drug under investigation (heroin or nicotine). The Breakpoint is the point at which participants stopped responding for the drug, i.e., the total number of clicks they were willing to provide in order to receive the drug.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measures of Subjective Drug Effects Most Commonly Indicative of Abuse Liability.</measure>
    <time_frame>Following 2 weeks of Pioglitazone (PIO) maintenance.</time_frame>
    <description>Visual analog scale ratings of &quot;Liking&quot; reported by the participant will be the primary endpoint (0-100 mm, 0=Not at all, 100=Extremely).</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Heroin Dependence</condition>
  <condition>Nicotine Dependence</condition>
  <arm_group>
    <arm_group_label>Placebo - Heroin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be maintained on 0 mg of Pioglitazone (PIO) prior to sessions assessing the abuse liability of heroin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PIO low dose - Heroin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be maintained on 15 mg of PIO prior to sessions assessing the abuse liability of heroin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PIO high dose - Heroin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be maintained on 45 mg of PIO prior to sessions assessing the abuse liability of heroin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo - Nicotine</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be maintained on 0 mg of PIO prior to sessions assessing the abuse liability of nicotine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PIO Low Dose - Nicotine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be maintained on 15 mg of PIO prior to sessions assessing the abuse liability of nicotine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PIO High Dose - Nicotine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be maintained on 45 mg of PIO prior to sessions assessing the abuse liability of nicotine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PIO</intervention_name>
    <description>0, 15, and 45 mg per day.</description>
    <arm_group_label>PIO low dose - Heroin</arm_group_label>
    <arm_group_label>PIO high dose - Heroin</arm_group_label>
    <arm_group_label>Placebo - Nicotine</arm_group_label>
    <arm_group_label>PIO Low Dose - Nicotine</arm_group_label>
    <arm_group_label>PIO High Dose - Nicotine</arm_group_label>
    <other_name>Actos</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo - Heroin</arm_group_label>
    <other_name>Actos</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  21-55 years of age

          -  Physically healthy

          -  Able to perform study procedures

        Exclusion Criteria:

          -  Pregnancy

          -  Physical dependence on any other drugs besides caffeine, heroin and nicotine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandra D. Comer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 13, 2011</study_first_submitted>
  <study_first_submitted_qc>July 14, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2011</study_first_posted>
  <results_first_submitted>August 31, 2015</results_first_submitted>
  <results_first_submitted_qc>July 11, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">July 13, 2017</results_first_posted>
  <last_update_submitted>July 11, 2017</last_update_submitted>
  <last_update_submitted_qc>July 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tobacco Use Disorder</mesh_term>
    <mesh_term>Heroin Dependence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
    <mesh_term>Heroin</mesh_term>
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be presented at conferences and published in a peer-reviewed journal.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo - Heroin</title>
          <description>Control condition for active arms.
Placebo: Placebo - Heroin</description>
        </group>
        <group group_id="P2">
          <title>Pio Low Dose - Heroin</title>
          <description>Low dose pio comparator.
Pioglitazone: 0, 15, and 45 mg per day.</description>
        </group>
        <group group_id="P3">
          <title>Pio High Dose - Heroin</title>
          <description>High dose pio comparator.
Pioglitazone: 0, 15, and 45 mg per day.</description>
        </group>
        <group group_id="P4">
          <title>Placebo - Nicotine</title>
          <description>Control condition for active arms.
Pioglitazone: 0, 15, and 45 mg per day.</description>
        </group>
        <group group_id="P5">
          <title>Pio Low Dose - Nicotine</title>
          <description>Low dose pio comparator.
Pioglitazone: 0, 15, and 45 mg per day.</description>
        </group>
        <group group_id="P6">
          <title>Pio High Dose - Nicotine</title>
          <description>High dose pio comparator.
Pioglitazone: 0, 15, and 45 mg per day.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="9"/>
                <participants group_id="P6" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo - Heroin</title>
          <description>Control condition for active arms.
Placebo: Placebo - Heroin</description>
        </group>
        <group group_id="B2">
          <title>Pio Low Dose - Heroin</title>
          <description>Low dose pio comparator.
Pioglitazone: 0, 15, and 45 mg per day.</description>
        </group>
        <group group_id="B3">
          <title>Pio High Dose - Heroin</title>
          <description>High dose pio comparator.
Pioglitazone: 0, 15, and 45 mg per day.</description>
        </group>
        <group group_id="B4">
          <title>Placebo - Nicotine</title>
          <description>Control condition for active arms.
Pioglitazone: 0, 15, and 45 mg per day.</description>
        </group>
        <group group_id="B5">
          <title>Pio Low Dose - Nicotine</title>
          <description>Low dose pio comparator.
Pioglitazone: 0, 15, and 45 mg per day.</description>
        </group>
        <group group_id="B6">
          <title>Pio High Dose - Nicotine</title>
          <description>High dose pio comparator.
Pioglitazone: 0, 15, and 45 mg per day.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="18"/>
            <count group_id="B4" value="15"/>
            <count group_id="B5" value="9"/>
            <count group_id="B6" value="17"/>
            <count group_id="B7" value="82"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="17"/>
                    <measurement group_id="B7" value="82"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="15"/>
                    <measurement group_id="B7" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="9"/>
                    <measurement group_id="B6" value="17"/>
                    <measurement group_id="B7" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Drug's Break Point</title>
        <description>Number of operant responses (mouse clicks) participants were willing to provide in order to receive the drug under investigation (heroin or nicotine). The Breakpoint is the point at which participants stopped responding for the drug, i.e., the total number of clicks they were willing to provide in order to receive the drug.</description>
        <time_frame>Following 2 weeks of Pioglitazone (PIO) maintenance.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo - Heroin</title>
            <description>Control condition for active arms.
Placebo: Placebo - Heroin</description>
          </group>
          <group group_id="O2">
            <title>Pio Low Dose- Heroin</title>
            <description>Low dose of Pio comparator</description>
          </group>
          <group group_id="O3">
            <title>Pio High Dose - Heroin</title>
            <description>High dose pio comparator.
Pioglitazone: 0, 15, and 45 mg per day.</description>
          </group>
          <group group_id="O4">
            <title>Placebo - Nicotine</title>
            <description>Control condition for active arms.
Pioglitazone: 0, 15, and 45 mg per day.</description>
          </group>
          <group group_id="O5">
            <title>Pio Low Dose- Nicotine</title>
            <description>Low dose Pio comparator.</description>
          </group>
          <group group_id="O6">
            <title>Pio High Dose - Nicotine</title>
            <description>High dose pio comparator.
Pioglitazone: 0, 15, and 45 mg per day.</description>
          </group>
        </group_list>
        <measure>
          <title>Drug's Break Point</title>
          <description>Number of operant responses (mouse clicks) participants were willing to provide in order to receive the drug under investigation (heroin or nicotine). The Breakpoint is the point at which participants stopped responding for the drug, i.e., the total number of clicks they were willing to provide in order to receive the drug.</description>
          <units>Mouse clicks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1037" spread="1763"/>
                    <measurement group_id="O2" value="1200" spread="272"/>
                    <measurement group_id="O3" value="2014" spread="2835"/>
                    <measurement group_id="O4" value="568" spread="652"/>
                    <measurement group_id="O5" value="722" spread="823"/>
                    <measurement group_id="O6" value="960" spread="1004"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Measures of Subjective Drug Effects Most Commonly Indicative of Abuse Liability.</title>
        <description>Visual analog scale ratings of &quot;Liking&quot; reported by the participant will be the primary endpoint (0-100 mm, 0=Not at all, 100=Extremely).</description>
        <time_frame>Following 2 weeks of Pioglitazone (PIO) maintenance.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo - Heroin</title>
            <description>Participants will be maintained on 0 mg of PIO prior to sessions assessing the abuse liability of heroin.
Placebo: Placebo</description>
          </group>
          <group group_id="O2">
            <title>Pio Low Dose- Heroin</title>
            <description>Participants will be maintained on 15 mg of PIO prior to assessing the abuse liability of heroin.</description>
          </group>
          <group group_id="O3">
            <title>Pio High Dose - Heroin</title>
            <description>Participants will be maintained on 45 mg of PIO prior to sessions assessing the abuse liability of heroin.</description>
          </group>
          <group group_id="O4">
            <title>Placebo - Nicotine</title>
            <description>Participants will be maintained on 0 mg of PIO prior to sessions assessing the abuse liability of nicotine.</description>
          </group>
          <group group_id="O5">
            <title>Pio Low Dose- Nicotine</title>
            <description>Participants will be maintained on 15 mg of PIO prior to assessing the abuse liability of nicotine.</description>
          </group>
          <group group_id="O6">
            <title>Pio High Dose - Nicotine</title>
            <description>Participants will be maintained on 45 mg of PIO prior to sessions assessing the abuse liability of nicotine</description>
          </group>
        </group_list>
        <measure>
          <title>Measures of Subjective Drug Effects Most Commonly Indicative of Abuse Liability.</title>
          <description>Visual analog scale ratings of &quot;Liking&quot; reported by the participant will be the primary endpoint (0-100 mm, 0=Not at all, 100=Extremely).</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="14"/>
                <count group_id="O4" value="13"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" spread="13"/>
                    <measurement group_id="O2" value="15" spread="9"/>
                    <measurement group_id="O3" value="19" spread="6"/>
                    <measurement group_id="O4" value="59" spread="9"/>
                    <measurement group_id="O5" value="68" spread="12"/>
                    <measurement group_id="O6" value="62.5" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo - Heroin</title>
          <description>Control condition for active arms.
Placebo: Placebo - Heroin</description>
        </group>
        <group group_id="E2">
          <title>Pio Low Dose - Heroin</title>
          <description>Low dose pio comparator.
Pioglitazone: 0, 15, and 45 mg per day.</description>
        </group>
        <group group_id="E3">
          <title>Pio High Dose - Heroin</title>
          <description>High dose pio comparator.
Pioglitazone: 0, 15, and 45 mg per day.</description>
        </group>
        <group group_id="E4">
          <title>Placebo - Nicotine</title>
          <description>Control condition for active arms.
Pioglitazone: 0, 15, and 45 mg per day.</description>
        </group>
        <group group_id="E5">
          <title>Pio Low Dose - Nicotine</title>
          <description>Low dose pio comparator.
Pioglitazone: 0, 15, and 45 mg per day.</description>
        </group>
        <group group_id="E6">
          <title>Pio High Dose - Nicotine</title>
          <description>High dose pio comparator.
Pioglitazone: 0, 15, and 45 mg per day.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="17"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sandra Comer PhD</name_or_title>
      <organization>New York State Psychiatric Institute</organization>
      <phone>646 774-6146</phone>
      <email>sdc10@columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

